Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Interactions among COX-2, GPIIIa and P2Y1 variants are associated with aspirin responsiveness and adverse events in patients with ischemic stroke.

Yi X, Han Z, Zhou Q, Lin J, Wang C.

Ther Adv Neurol Disord. 2017 Mar;10(3):161-170. doi: 10.1177/1756285616681943. Epub 2016 Dec 1.

2.
3.

The lack of aspirin resistance in patients with coronary artery disease.

Homoródi N, Kovács EG, Leé S, Katona É, Shemirani AH, Haramura G, Balogh L, Bereczky Z, Szőke G, Péterfy H, Kiss RG, Édes I, Muszbek L.

J Transl Med. 2016 Mar 15;14:74. doi: 10.1186/s12967-016-0827-7.

4.

Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapy.

Timur AA, Murugesan G, Zhang L, Barnard J, Bhatt DL, Kottke-Marchant K.

Thromb Res. 2014 Jul;134(1):96-104. doi: 10.1016/j.thromres.2014.04.023. Epub 2014 Apr 29.

5.

Aspirin resistance: a clinical review focused on the most common cause, noncompliance.

Schwartz KA.

Neurohospitalist. 2011 Apr;1(2):94-103. doi: 10.1177/1941875210395776.

6.

Aspirin treatment failure: is this a real phenomenon? A review of the aetiology and how to treat it.

Shahid F, Chahal CA, Akhtar MJ.

JRSM Short Rep. 2013 Apr;4(4):30. doi: 10.1177/2042533313475576. Epub 2013 Mar 27.

7.

Protocol for a systematic review of the diagnostic and prognostic utility of tests currently available for the detection of aspirin resistance in patients with established cardiovascular or cerebrovascular disease.

Raichand S, Moore D, Riley RD, Lordkipanidzé M, Dretzke J, O'Donnell J, Jowett S, Bayliss S, Fitzmaurice DA.

Syst Rev. 2013 Feb 26;2:16. doi: 10.1186/2046-4053-2-16. Review.

8.

Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin.

Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, FitzGerald GA.

Circulation. 2013 Jan 22;127(3):377-85. doi: 10.1161/CIRCULATIONAHA.112.117283. Epub 2012 Dec 4.

9.

Aspirin resistance: Fact or fiction? A point of view.

Mehta JL, Mohandas B.

World J Cardiol. 2010 Sep 26;2(9):280-8. doi: 10.4330/wjc.v2.i9.280.

10.

Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care.

Cohen M.

Mayo Clin Proc. 2009 Feb;84(2):149-60. doi: 10.1016/S0025-6196(11)60823-9. Review.

11.

'Aspirin resistance' or treatment non-compliance: which is to blame for cardiovascular complications?

Shantsila E, Lip GY.

J Transl Med. 2008 Aug 29;6:47. doi: 10.1186/1479-5876-6-47.

12.

Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients.

Schwartz KA, Schwartz DE, Barber K, Reeves M, De Franco AC.

J Transl Med. 2008 Aug 29;6:46. doi: 10.1186/1479-5876-6-46.

13.

Pharmacogenetics of aspirin resistance: a comprehensive systematic review.

Goodman T, Ferro A, Sharma P.

Br J Clin Pharmacol. 2008 Aug;66(2):222-32. doi: 10.1111/j.1365-2125.2008.03183.x. Epub 2008 Apr 22. Review.

14.

Aspirin resistance: What is the risk of cardiovascular morbidity?

Elwood P, Morgan G.

BMJ. 2008 Feb 9;336(7639):291. doi: 10.1136/bmj.39479.465706.3A. No abstract available.

15.

Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions.

Undas A, Brummel-Ziedins KE, Mann KG.

Blood. 2007 Mar 15;109(6):2285-92. Epub 2006 Dec 5. Review.

Supplemental Content

Support Center